Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. https://doi.org/10.3322/caac.21820.

Article  PubMed  Google Scholar 

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. https://doi.org/10.1016/j.breast.2022.08.010.

Article  PubMed  PubMed Central  Google Scholar 

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23. https://doi.org/10.1093/annonc/mdt303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90. https://doi.org/10.1038/nrclinonc.2016.66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48. https://doi.org/10.1056/NEJMra1001389.

Article  CAS  PubMed  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic Triple-Negative breast cancer. N Engl J Med. 2021;384:1529–41. https://doi.org/10.1056/NEJMoa2028485.

Article  CAS  PubMed  Google Scholar 

Fornaro M, Dell’Arciprete R, Stella M, Bucci C, Nutini M, Capri MG, et al. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer. 1995;62:610–8. https://doi.org/10.1002/ijc.2910620520.

Article  CAS  PubMed  Google Scholar 

Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022;10:1403. https://doi.org/10.21037/atm-22-5976.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dum D, Taherpour N, Menz A, Hoflmayer D, Volkel C, Hinsch A, et al. Trophoblast cell surface antigen 2 expression in human tumors: A tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245–58. https://doi.org/10.1159/000522206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012;4:472–85. https://doi.org/10.1002/emmm.201200222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222–33. https://doi.org/10.1038/onc.2012.36.

Article  CAS  PubMed  Google Scholar 

Liao Q, Zhang R, Ou Z, Ye Y, Zeng Q, Wang Y, et al. TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs. Mol Ther Oncol. 2024;32:200762. https://doi.org/10.1016/j.omton.2024.200762.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46:944–53. https://doi.org/10.1016/j.ejca.2009.12.019.

Article  CAS  PubMed  Google Scholar 

Rowe SP, Pomper MG. Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin. 2022;72:333–52. https://doi.org/10.3322/caac.21713.

Article  PubMed  Google Scholar 

Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28:1111–6. https://doi.org/10.1093/annonc/mdx053.

Article  CAS  PubMed  Google Scholar 

Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51:380–94. https://doi.org/10.1007/s00259-023-06454-3.

Article  CAS  PubMed  Google Scholar 

Huang W, Zhang Y, Cao M, Wu Y, Jiao F, Chu Z, et al. ImmunoPET imaging of Trop2 in patients with solid tumours. EMBO Mol Med. 2024;16:1143–61. https://doi.org/10.1038/s44321-024-00059-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest. 2024. https://doi.org/10.1172/JCI185408.

Article  PubMed  PubMed Central  Google Scholar 

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.

Article  CAS  PubMed  Google Scholar 

Nelson BE, Meric-Bernstam F. Leveraging TROP2 Antibody-Drug conjugates in solid tumors. Annu Rev Med. 2024;75:31–48. https://doi.org/10.1146/annurev-med-071322-065903.

Article  CAS  PubMed  Google Scholar 

Zimmers SM, Browne EP, Williams KE, Jawale RM, Otis CN, Schneider SS, et al. TROP2 methylation and expression in tamoxifen-resistant breast cancer. Cancer Cell Int. 2018;18:94. https://doi.org/10.1186/s12935-018-0589-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vidula N, Yau C, Rugo H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat. 2022;194:569–75. https://doi.org/10.1007/s10549-022-06660-x.

Article  CAS  PubMed  Google Scholar 

Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab Govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32:1148–56. https://doi.org/10.1016/j.annonc.2021.06.002.

Article  CAS  Google Scholar 

Huang W, Zhang Y, Xiao X, Yang Q, Mixdorf JC, Sun X, et al. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [(64)Cu]Cu-NOTA-Trodelvy-F(ab’)(2). Eur J Nucl Med Mol Imaging. 2025;52:3223–37. https://doi.org/10.1007/s00259-025-07167-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang D, Chu Z, Wu Y, Zhang Y, Liu Y, Ge Q, et al. [(68)Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. Eur J Nucl Med Mol Imaging. 2025;52:4547–57. https://doi.org/10.1007/s00259-025-07326-8.

Article  CAS  PubMed  Google Scholar 

Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Investig. 2024;135. https://doi.org/10.1172/jci185408.

Huang W, Cao M, Wu Y, Zhang Y, An S, Pan X, et al. Immuno-PET/CT imaging of Trop2 with [(18)F]AlF-RESCA-T4 differentiates lung cancer from inflammation. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2024;65:1904–10. https://doi.org/10.2967/jnumed.124.268751.

Article  CAS  Google Scholar 

Jiang D, Chu Z, Wu Y, Zhang Y, Liu Y, Ge Q, et al. [(68)Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. Eur J Nucl Med Mol Imaging. 2025. https://doi.org/10.1007/s00259-025-07326-8.

Article